Nonalcoholic fatty liver disease in patients with type 2 diabetes (Q44797472)

6 December 2017

Nonalcoholic fatty liver disease in patients with type 2 diabetes (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

6 December 2017

0 references

0 references

1 reference

1 reference

Zobair M Younossi

1

1 reference

6 December 2017

Terry Gramlich

2

1 reference

6 December 2017

Christi A Matteoni

3

1 reference

6 December 2017

Navdeep Boparai

4

1 reference

6 December 2017

Arthur J McCullough

5

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Clinical Gastroenterology and Hepatology

6 December 2017

1 reference

6 December 2017

2

1 reference

6 December 2017

3

1 reference

6 December 2017

262-265

1 reference

Nonalcoholic fatty liver disease: an agenda for clinical research

6 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Non-alcoholic fatty liver disease: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Clinical features and natural history of nonalcoholic steatosis syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Nonalcoholic steatohepatitis: a study of 49 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Nonalcoholic steatohepatitis: An expanded clinical entity

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Recent advances in our understanding of insulin action and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Is obesity an inflammatory condition?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Platelet activation in obese women: role of inflammation and oxidant stress

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Evidence for a relationship between oxidative stress and insulin action in non-insulin-dependent (type II) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Glucose and reactive oxygen species

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Hepatic iron and nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900014-X

7 January 2021

10.1016/S1542-3565(04)00014-X

Identifiers

DOI

1 reference

6 December 2017

1 reference